~ Buy the REZZAYO (rezafungin acetate) Drug Profile, 2024 PDF Report in the Report Store ~

REZZAYO Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Rezzayo, and when can generic versions of Rezzayo launch?

Rezzayo is a drug marketed by Cidara Theraps and is included in one NDA. There are seven patents protecting this drug.

This drug has ninety-two patent family members in twenty-four countries.

The generic ingredient in REZZAYO is rezafungin acetate. One supplier is listed for this compound. Additional details are available on the rezafungin acetate profile page.

DrugPatentWatch^® Generic Entry Outlook for Rezzayo

Rezzayo will be eligible for patent challenges on March 22, 2027. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 22, 2035. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

Try a Trial

Summary for REZZAYO

International Patents:	92
US Patents:	7
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Drug Prices:	Drug price information for REZZAYO
What excipients (inactive ingredients) are in REZZAYO?	REZZAYO excipients list
DailyMed Link:	REZZAYO at DailyMed

Drug patent expirations by year for REZZAYO

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for REZZAYO

Generic Entry Date for REZZAYO^: ⤷ Try a Trial* Constraining patent/regulatory exclusivity: GENERATING ANTIBIOTIC INCENTIVES NOW NDA: 217417 Dosage: POWDER;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for REZZAYO

Drug Class	Echinocandin Antifungal

Anatomical Therapeutic Chemical (ATC) Classes for REZZAYO

J02AX	Other antimycotics for systemic use
J02A	ANTIMYCOTICS FOR SYSTEMIC USE
J02	ANTIMYCOTICS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

US Patents and Regulatory Information for REZZAYO

REZZAYO is protected by seven US patents and four FDA Regulatory Exclusivities.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of REZZAYO is ⤷ Try a Trial.

This potential generic entry date is based on GENERATING ANTIBIOTIC INCENTIVES NOW.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting REZZAYO

Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF CANDIDEMIA AND INVASIVE CANDIDIASIS WITH REZAFUNGIN BY INTRAVENOUS ADMINISTRATION

FDA Regulatory Exclusivity protecting REZZAYO

FOR USE IN PATIENTS 18 YEARS OF AGE OR OLDER WHO HAVE LIMITED OR NO ALTERNATIVE OPTIONS FOR THE TREATMENT OF CANDIDEMIA AND INVASIVE CANDIDIASIS
Exclusivity Expiration: ⤷ Try a Trial

NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Try a Trial

GENERATING ANTIBIOTIC INCENTIVES NOW
Exclusivity Expiration: ⤷ Try a Trial

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cidara Theraps	REZZAYO	rezafungin acetate	POWDER;INTRAVENOUS	217417-001	Mar 22, 2023		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial	Y	Y		⤷ Try a Trial
Cidara Theraps	REZZAYO	rezafungin acetate	POWDER;INTRAVENOUS	217417-001	Mar 22, 2023		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial	Y	Y		⤷ Try a Trial
Cidara Theraps	REZZAYO	rezafungin acetate	POWDER;INTRAVENOUS	217417-001	Mar 22, 2023		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial	Y	Y		⤷ Try a Trial
Cidara Theraps	REZZAYO	rezafungin acetate	POWDER;INTRAVENOUS	217417-001	Mar 22, 2023		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
Cidara Theraps	REZZAYO	rezafungin acetate	POWDER;INTRAVENOUS	217417-001	Mar 22, 2023		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial	Y	Y		⤷ Try a Trial
Cidara Theraps	REZZAYO	rezafungin acetate	POWDER;INTRAVENOUS	217417-001	Mar 22, 2023		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial	Y	Y		⤷ Try a Trial
Cidara Theraps	REZZAYO	rezafungin acetate	POWDER;INTRAVENOUS	217417-001	Mar 22, 2023		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial	Y			⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for REZZAYO

See the table below for patents covering REZZAYO around the world.

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Title	Estimated Expiration
Portugal	2827710		⤷ Try a Trial
Denmark	2827710		⤷ Try a Trial
Canada	3053850	AGENTS ANTIFONGIQUES ET UTILISATIONS ASOCIEES (ANTIFUNGAL AGENTS AND USES THEREOF)	⤷ Try a Trial
Poland	2827710		⤷ Try a Trial
Hungary	E047439		⤷ Try a Trial
Japan	2017171658	エキノキャンディン系化合物のための投与レジメン (DOSING REGIMENS FOR ECHINOCANDIN CLASS COMPOUNDS)	⤷ Try a Trial
Portugal	2680873		⤷ Try a Trial
>Country	>Patent Number	>Title	>Estimated Expiration